Precision Medicine Enhanced: turn Bio Integrates ARMS Technology

Turn Biotechnologies, a frontrunner in epigenetic reprogramming, has recently announced the acquisition of the innovative ARMS (Arrdc1-mediated microvesicles) technology. This strategic move dramatically broadens the spectrum of treatable organs,tissues,and cells,promising safer and more precise delivery of epigenetic therapies.

The acquisition includes licensing the ARMS delivery technology from Harvard university, along with all associated assets from Vesige therapeutics, based in Cambridge, Massachusetts. This integration marks a significant leap forward in Turn Bio’s mission to combat age-related diseases through targeted cellular rejuvenation.

Synergistic Platforms: Eturna™ LNP and ARMS Unite

The incorporation of ARMS into Turn Bio’s existing Eturna™ LNP delivery platform amplifies the potential of their ERA™ technology. ERA™ leverages mRNA to produce proteins that reprogram the cellular epigenome, effectively restoring function and combating age-related decline. The synergy between these platforms allows for the delivery of larger and more diverse payloads, including gene editors, proteins, and RNA-based therapies.

This expanded delivery capacity positions Turn Bio at the forefront of regenerative medicine,enabling them to tackle previously untreatable conditions with unprecedented precision. As of 2024, the global regenerative medicine market was valued at approximately $52 billion, with projections estimating a rise to over $120 billion by 2032, highlighting the immense potential of this field.

Pipeline Acceleration: Ophthalmology, Dermatology, and Immunotherapy

the acquired license and associated intellectual property will expedite the progress of turn Bio’s pipeline candidates, particularly in ophthalmology and immune cell rejuvenation. ARMS will bolster the development of these candidates alongside TRN-001, a skin rejuvenation therapy utilizing the company’s Eturna platform. Preclinical data demonstrates ARMS’ effectiveness in delivering therapies to various tissues, including the retina, lungs, nervous system, liver, and spleen.

Executive Viewpoint: Shaping the Future of Healthcare

For Turn Bio, ARMS technology is of central importance for our mission to use the power of epigenetics and to shape what it can mean for the future of health care in old age. This will enable us to give our therapies with an exact precision if necessary.
Anja Krammer, Managing Director, Turn Biotechnologies

It is also exciting that this technology enables us to transport larger and more diverse loads, including proteins and gene and epigenetics editors. This unprecedented delivery capacity means that Turn bio will help to define the future of regenerative medicine.
Anja Krammer, Managing Director, turn Biotechnologies

ARMS Technology: A deep Dive

The ARMS platform (Arrdc1-mediated microvesicle) utilizes human extracellular vesicles to transport signaling molecules between cells. Developed by researchers at Harvard University, these vesicles are engineered to efficiently deliver therapeutic agents into cells, offering a highly effective delivery system for epigenetic modulators. Key features of the technology include:

• Efficient encapsulation of various epigenetic modulators
• Targeted delivery to specific cell types
• Reduced off-target effects

ARMS overcomes limitations of other delivery systems and complements Turn Bio’s Eturna™ platform, which uses lipid nanoparticles for drug delivery. The ARMS platform is biocompatible, reusable, easily manufactured, tissue-specific, and capable of transporting large payloads.

Epigenetic Reprogramming: Restoring Cellular Function

Turn Bio’s core technology focuses on restoring the epigenome to a more youthful and functional state,enabling the treatment of diseases and conditions where epigenetics play a crucial role. This approach allows for the modulation of gene expression to correct or restore normal cell function in conditions such as skin aging, vision loss, muscle loss, joint degeneration, and other age-related diseases. Recent studies have shown that epigenetic changes are increasingly recognized as key drivers of aging and age-related diseases, making this approach highly promising.

Investor Confidence: Bayer Healthcare, Morningside Group, and Alexandria ventures

The ARMS technology has garnered significant attention from leading investors, including Bayer Healthcare LLC, Morningside Group Ltd., and Alexandria ventures, underscoring the potential of this technology to revolutionize the field of regenerative medicine.